Atom Investors LP Reduces Position in Urogen Pharma $URGN

Atom Investors LP cut its holdings in shares of Urogen Pharma (NASDAQ:URGN) by 19.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 234,423 shares of the company’s stock after selling 57,539 shares during the quarter. Atom Investors LP owned approximately 0.50% of Urogen Pharma worth $5,490,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in URGN. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Urogen Pharma by 27.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after buying an additional 486 shares during the period. Russell Investments Group Ltd. increased its position in shares of Urogen Pharma by 1,594.4% during the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after buying an additional 3,125 shares during the period. Osaic Holdings Inc. increased its position in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Urogen Pharma by 422.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after buying an additional 5,571 shares during the period. Finally, ProShare Advisors LLC bought a new stake in shares of Urogen Pharma during the fourth quarter valued at about $206,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Trading Up 3.5%

URGN stock opened at $31.95 on Wednesday. The company’s 50 day moving average is $26.23 and its 200 day moving average is $22.88. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -11.62 and a beta of 1.59. Urogen Pharma has a 1-year low of $12.73 and a 1-year high of $32.37.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.01. The company had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. As a group, sell-side analysts forecast that Urogen Pharma will post -0.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

URGN has been the topic of several analyst reports. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a research report on Tuesday, June 2nd. LADENBURG THALM/SH SH initiated coverage on Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Monday, April 20th. Jefferies Financial Group upgraded Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Urogen Pharma in a research report on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Urogen Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Insider Buying and Selling at Urogen Pharma

In related news, insider Mark Schoenberg sold 5,222 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $27.30, for a total value of $142,560.60. Following the transaction, the insider directly owned 139,763 shares in the company, valued at approximately $3,815,529.90. This represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.80% of the company’s stock.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.